**A Case of Adverse Drug Reaction after consumption of Chinese medicine Preparation "Zhuanggu Guanjie Wan"**

The Department of Health was informed by Hospital Authority about a suspected Adverse Drug Reaction (ADR) report in April that a patient diagnosed to have liver derangement after consuming a Chinese medicine preparation "Zhuanggu Guanjie Wan" purchased in the Mainland. The product is a patent medicine in the mainland (國藥准字 Z44023377) for treating degenerative bone and joint problem. The ingredients were listed in the Chinese Pharmacopoeia (2005 version) comprising Rhizoma Cibotii, Herba Epimedii, Radix Angelicae Pubescentis, Rhizoma Drynariae, Radix Dipsaci, Fructus Psoraleae, Herba Taxilli, Caulis Spatholobi, Radix Rehmanniae Preparata, Radix Aucklandiae, Olibanum, and Myrrha.

The State Food and Drug Administration (SFDA) of the People's Republic of China received some 160 ADR cases related to this product from 2001-2008, and about 50 patients had reported deranged liver function [SFDA's Adverse Drug Reaction Report ($16^{th}$ issue) dated August 2008]. Although causative mechanism of liver derangement was unclear, SFDA advised that the public should use this product under medical instruction.

This case was further reviewed by local experts of the Hong Kong Poison Control Network. It was agreed that the case was a possible ADR case. The Department of Health has notified SFDA about the case, and will maintain vigilance on this medicine preparation. No similar case has been reported as of today.

Members of the public were cautioned against possible adverse effect of liver derangement after consumption of "Zhuanggu Guanjie Wan". They should obtain medical advice before taking any medication, and consult medical professionals if they have symptoms after taking any medications.

23 July 2010